NCT05761652

Brief Summary

Based on the characteristics of symptoms, differences in physical and chemical examinations and tests, and characteristics of traditional Chinese medicine (TCM) disease differentiation and syndrome differentiation, the evaluation indicators for the clinical early warning model were screened, and the "three-level early warning mechanism for COVID-19 patients at high risks, with progression to severe cases and sequelae was constructed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
378

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 8, 2023

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 9, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

March 9, 2023

Status Verified

February 1, 2023

Enrollment Period

1.2 years

First QC Date

March 8, 2023

Last Update Submit

March 8, 2023

Conditions

Keywords

Early Warning Model

Outcome Measures

Primary Outcomes (4)

  • General Data:

    including age, underlying diseases, body weight, occupation, smoking, alcohol drinking, salt intake and exercise

    Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

  • Environment Indicators:

    air temperature, humidity, and air quality

    Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

  • Auxiliary Examination Indicators:

    blood routine (lymphocyte count, lymphocyte/neutrophil ratio), four coagulation items (PT, APTT, TT, FIB), D-Di, C-reactive protein, erythrocyte sedimentation rate, liver function (ALT, AST, ALP), renal function (BUN, Cr), blood glucose, lung CT

    Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

  • TCM based Evaluation:

    TCM constitution differentiation With reference to the Classification and Determination of Constitutions in TCM issued by the China Association of Traditional Chinese Medicine. There are nine constitution types based on TCM syndrome differentiation

    Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

Study Arms (2)

Modeling group

Other: Observe and record

Validation group

Other: Observe and record

Interventions

The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.

Modeling groupValidation group

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

COVID-19 patients

You may qualify if:

  • Meeting the diagnostic criteria of mild and moderate types of COVID-19 disease described in the "Diagnostic and Treatment Protocol for Novel Coronavirus Pneumonia (Trial version 9)" \[9\];
  • Age ≥18 years old and ≤90years old;
  • Not more than 5 days after the occurrence of the first symptom (or confirmed onset);
  • The subject agrees to participate the study and have signed the informed consent form by paper signature, electronic signature of mobile software or voice authorization.

You may not qualify if:

  • Pregnant or lactating women;
  • Patients complicated with severe heart, liver, kidney, blood system and other primary diseases and mental disorders.
  • Patients with disturbance of consciousness, aphasia, dementia and other conditions that prevent them from cooperating with the clinical investigators
  • Patients with incomplete study data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijin, 100091, China

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

Records

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesOrganization and AdministrationHealth Services AdministrationHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Central Study Contacts

Yanhong Zhang, doctor

CONTACT

Maorong Fan, doctor

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 8, 2023

First Posted

March 9, 2023

Study Start

December 1, 2022

Primary Completion

February 1, 2024

Study Completion

June 1, 2024

Last Updated

March 9, 2023

Record last verified: 2023-02

Locations